The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II study of docosahexaenoic acid (DHA) in patients (pts) with a history of breast cancer (BC), premalignant lesions, or benign breast disease.
Ayca Gucalp
No relevant relationships to disclose
Patrick Glyn Morris
No relevant relationships to disclose
Xi Kathy Zhou
No relevant relationships to disclose
Dilip D. Giri
No relevant relationships to disclose
Neil M. Iyengar
No relevant relationships to disclose
Katherine D. Crew
No relevant relationships to disclose
Dawn L. Hershman
No relevant relationships to disclose
Judy Ellen Garber
No relevant relationships to disclose
Julie R. Nangia
No relevant relationships to disclose
Elise D. Cook
No relevant relationships to disclose
Lana Vornik
No relevant relationships to disclose
Barbara Karen Dunn
No relevant relationships to disclose
Brandy M. Heckman-Stoddard
No relevant relationships to disclose
Kathleen Foster
No relevant relationships to disclose
Powel Brown
No relevant relationships to disclose
Andrew Dannenberg
No relevant relationships to disclose
Clifford A. Hudis
No relevant relationships to disclose